Literature DB >> 20309006

Tumor size and survival in breast cancer--a reappraisal.

William D Foulkes1, Jorge S Reis-Filho, Steven A Narod.   

Abstract

The size of a breast cancer at diagnosis has conventionally been thought of as a fundamental and critical determinant of clinical outcome. However, the tendency of some subtypes of breast cancer to behave aggressively, despite being small (</=1 cm in diameter), questions the premise that cancer size should always be considered in treatment decisions. Although there is an association between tumor size and lymph-node involvement for most tumor types, this pattern is not invariable. We speculate that the uncoupling of tumor size, lymph-node status and prognosis in some subtypes of breast cancers might reflect an underlying disproportionate relationship between the number of cancer cells with metastatic potential and the size of the cancer. Alternatively, some small cancers might harbor cells that are inherently aggressive and are likely to metastasize. These observations have implications for the screening and treatment of breast cancers, particularly for women with basal-like and BRCA1-related breast cancers.

Entities:  

Mesh:

Year:  2010        PMID: 20309006     DOI: 10.1038/nrclinonc.2010.39

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  54 in total

1.  High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Authors:  Ana M Gonzalez-Angulo; Jennifer K Litton; Kristine R Broglio; Funda Meric-Bernstam; Ronjay Rakkhit; Fatima Cardoso; Florentia Peintinger; Emer O Hanrahan; Aysegul Sahin; Merih Guray; Denis Larsimont; Francesco Feoli; Heidi Stranzl; Thomas A Buchholz; Vicente Valero; Richard Theriault; Martine Piccart-Gebhart; Peter M Ravdin; Donald A Berry; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

2.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  A Gompertzian model of human breast cancer growth.

Authors:  L Norton
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

Review 4.  The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.

Authors:  Emiliano Honrado; Javier Benítez; José Palacios
Journal:  Mod Pathol       Date:  2005-10       Impact factor: 7.842

5.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

Authors:  Koei Chin; Sandy DeVries; Jane Fridlyand; Paul T Spellman; Ritu Roydasgupta; Wen-Lin Kuo; Anna Lapuk; Richard M Neve; Zuwei Qian; Tom Ryder; Fanqing Chen; Heidi Feiler; Taku Tokuyasu; Chris Kingsley; Shanaz Dairkee; Zhenhang Meng; Karen Chew; Daniel Pinkel; Ajay Jain; Britt Marie Ljung; Laura Esserman; Donna G Albertson; Frederic M Waldman; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

6.  Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.

Authors:  Salvatore Pece; Daniela Tosoni; Stefano Confalonieri; Giovanni Mazzarol; Manuela Vecchi; Simona Ronzoni; Loris Bernard; Giuseppe Viale; Pier Giuseppe Pelicci; Pier Paolo Di Fiore
Journal:  Cell       Date:  2010-01-08       Impact factor: 41.582

7.  A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.

Authors:  Madeleine Tilanus-Linthorst; Leon Verhoog; Inge-Marie Obdeijn; Karina Bartels; Marian Menke-Pluymers; Alexander Eggermont; Jan Klijn; Hanne Meijers-Heijboer; Theo van der Kwast; Cecile Brekelmans
Journal:  Int J Cancer       Date:  2002-11-01       Impact factor: 7.396

8.  Heterogeneity in cancer: cancer stem cells versus clonal evolution.

Authors:  Mark Shackleton; Elsa Quintana; Eric R Fearon; Sean J Morrison
Journal:  Cell       Date:  2009-09-04       Impact factor: 41.582

Review 9.  Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.

Authors:  P Sutcliffe; S Hummel; E Simpson; T Young; A Rees; A Wilkinson; F Hamdy; N Clarke; J Staffurth
Journal:  Health Technol Assess       Date:  2009-01       Impact factor: 4.014

10.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Authors:  Gabriella Honeth; Pär-Ola Bendahl; Markus Ringnér; Lao H Saal; Sofia K Gruvberger-Saal; Kristina Lövgren; Dorthe Grabau; Mårten Fernö; Ake Borg; Cecilia Hegardt
Journal:  Breast Cancer Res       Date:  2008-06-17       Impact factor: 6.466

View more
  44 in total

1.  Disappearing breast cancers.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2012-04       Impact factor: 3.677

2.  Re. Multimodality breast cancer screening in women with a familial or genetic predisposition.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2010-11       Impact factor: 3.677

Review 3.  The influence of subclonal resistance mutations on targeted cancer therapy.

Authors:  Michael W Schmitt; Lawrence A Loeb; Jesse J Salk
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

4.  Does Age Matter? Estimating Risks of Locoregional Recurrence After Breast-conservative Surgery.

Authors:  Gianluca Vanni; Marco Materazzo; Marco Pellicciaro; Ljuba Morando; Ilaria Portarena; Lucia Anemona; Maria Rolando D'Angelillo; Rosaria Barbarino; Agostino Chiaravalloti; Rosaria Meucci; Tommaso Perretta; Camilla Deiana; Paolo Orsaria; Jonathan Caspi; Chiara Adriana Pistolese; Oreste Claudio Buonomo
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

5.  An integrated microfluidic platform for size-selective single-cell trapping of monocytes from blood.

Authors:  Do-Hyun Lee; Xuan Li; Alan Jiang; Abraham P Lee
Journal:  Biomicrofluidics       Date:  2018-09-19       Impact factor: 2.800

6.  Size surprise? Tumour size, nodal status, and outcome after breast cancer.

Authors:  W D Foulkes
Journal:  Curr Oncol       Date:  2012-10       Impact factor: 3.677

7.  Is breast cancer staging obsolete?

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

8.  Reflections on screening mammography and the early detection of breast cancer: A Countercurrents Series.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

Review 9.  Off-tumor target--beneficial site for antiangiogenic cancer therapy?

Authors:  Yihai Cao
Journal:  Nat Rev Clin Oncol       Date:  2010-08-03       Impact factor: 66.675

10.  Therapeutic effect of taxanes on metastatic breast cancer of various immunohistochemical subtypes.

Authors:  Ippei Fukada; Kazuhiro Araki; Kokoro Kobayashi; Takayuki Kobayashi; Rie Horii; Futoshi Akiyama; Shunji Takahashi; Takuji Iwase; Yoshinori Ito
Journal:  Oncol Lett       Date:  2016-05-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.